Table 1. Main characteristics of the included studies.
| Study | Year | Tumor type | No. of Patients | Male/Female | median age (range) (year) | CD57+ lymphocytes: High/Low | Tumor stage | median follow-up date (months) | Survival | Quality Score (NOS) |
|---|---|---|---|---|---|---|---|---|---|---|
| Chen, Y.F et al. [5] | 2016 | Colorectal cancer | 300 | 158/142 | < 60: 48%; ≥ 60: 52% |
NR | I–IV | 62.9 ± 29.3 | OS, DFS | 6 |
| Chaput, N. et al. [6] | 2013 | Colorectal cancer | 196 | 108/88 | (27, 86) | 56/100 | II–III | ≥ 24 | OS, DFS | 7 |
| Liska, V. et al. [7] | 2012 | Colorectal cancer | 150 | 93/57 | NR | 34/11 | NR | NR | OS | 6 |
| Sconocchia, G. et al. [8] | 2011 | Colorectal cancer | 1400 | NR | 71 (30, 96) | 189/1070 | NR | NR | OS | 6 |
| Menon, A. G. et al. [9] | 2004 | Colorectal cancer | 93 | 56/37 | < 50: 13%; ≥ 50: 87% |
30/62 | II–III | 73.2 (1.2, 223.2) |
DFS | 7 |
| Coca, S. et al. [10] | 1997 | Colorectal cancer | 186 | 110/76 | 63.4 (29, 84) | 25/132 | I–III | ≥ 60 | OS, DFS | 6 |
| Gao, Q. et al. [11] | 2012 | Hepatocellular carcinoma | 206 | 186/20 | ≤ 49: 50.5%; > 49: 49.5% |
NR | I–III | 48.1 (3.4, 111.9) |
OS, DFS | 8 |
| Zhao, J. J. et al. [12] | 2014 | Hepatocellular carcinoma | 163 | 131/32 | < 50: 57%; ≥ 50: 43% |
82/81 | NR | NR | OS | 7 |
| Liu, K. et al. [13] | 2015 | Gastric cancer | 166 | 41/125 | < 60: 60.8%; ≥ 60: 39.2% |
83/83 | I–IV | 65.88 | OS | 8 |
| Ishigami, S. et al. [14] | 2000 | Gastric cancer | 169 | 121/48 | 63.8 (30, 87) | 53/116 | NR | 63 | OS | 7 |
| Ishigami, Sumiya. et al. [15] | 2000 | Gastric cancer | 146 | 108/38 | 63.8 (30, 87) | 39/107 | I–IV | 87 | OS | 7 |
| Lv, L. et al. [16] | 2011 | Esophageal carcinoma | 181 | 141/40 | < 60: 58%; ≥ 60: 42% |
91/90 | I–IV | NR | OS | 8 |
| Hsia, J. Y. et al. [17] | 2005 | Esophageal carcinoma | 38 | 38/0 | < 60: 47.4%; ≥ 60: 52.6% |
14/24 | I–IV | NR | OS | 6 |
| Fang, J. et al. [18] | 2017 | Head and neck carcinoma | 78 | 57/21 | 60 (24, 82) | 34/44 | I–IV | 48 (29, 93) | OS | 7 |
| Taghavi, N. et al. [19] | 2016 | Head and neck carcinoma | 57 | 27/30 | 62.89 (34, 91) | 26/31 | NR | 29 (10, 85) | OS | 7 |
| Fraga, C. A. et al. [20] | 2012 | Head and neck carcinoma | 70 | 61/9 | 54.9 (36, 88) | 35/35 | NR | NR | OS | 6 |
| Karpathiou, G. et al. [21] | 2017 | Head and neck carcinoma | 152 | 128/24 | 58.5 (40, 88) | 71/81 | I–IV | 24 (3, 84) | OS | 7 |
| Hernandez-Prieto, S. et al. [22] | 2015 | Non-small cell lung cancer | 84 | 72/12 | 66.5 ±10.2 | 29/55 | I–II | 45.97 | DFS | 6 |
| Villegas, F. R. et al. [23] | 2002 | Non-small cell lung cancer | 50 | 49/1 | (50, 81) | 21/29 | I–IIIA | (6.2, 149.3) | OS | 6 |
| Takanami, I. et al. [24] | 2001 | Non-small cell lung cancer | 150 | 83/67 | 61 (30, 81) | 53/97 | I–IIIA | (60, 120) | OS | 8 |
| Donskov, F. et al. [25] | 2006 | Renal Cell Carcinoma | 120 | 85/35 | 57 (19, 74) | 34/51 | IV | 7 (32, 73) | OS | 7 |
| Li, K. et al. [26] | 2009 | Ovarian Cancer | 82 | 0/82 | (26, 80) | 33/49 | I–IV | (1, 154) | OS | 6 |
| Ohnishi, K. et al. [27] | 2016 | Endometrial Carcinoma | 79 | 0/79 | 59 (30, 74) | 37/38 | I–IV | NR | OS | 7 |
| Hansen, B. D. et al. [28] | 2006 | Melanoma | 27 | 16/11 | 49 (31, 65) | 13/12 | IV | 8.9 (1, 35) | OS | 6 |
| Blaker, Y. N. et al. [29] | 2016 | Lymphoma | 52 | NR | NR | NR | NR | 120 (15.6, 40.8) |
OS | 6 |
| Wangerin, H. et al. [30] | 2014 | Prostate cancer | 3261 | 3261/0 | 62 | NR | NR | 34 (1, 144) | OS | 6 |